A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer - Trial NCT06099769
Access comprehensive clinical trial information for NCT06099769 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 201 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 2
Oct 18, 2023
Oct 01, 2027
Primary Outcome
progression-free survival (PFS)
Summary
The researchers are doing this study to find out if the study drug, enzalutamide, alone or
 combined with the study drug, mifepristone, is effective in treating advanced or metastatic
 androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen
 receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as
 standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099769
Non-Device Trial